CD274 and breast carcinoma: In the breast cancer subtype, TNBC was more widely treated with immunotherapy because of the emergence of effective biomarkers such as PD-L1 and well-founded classification of full inflamed (FI), stroma restricted (SR), margin restricted (MR), and immune desert (ID) subtypes (34).